Tiziana Life Sciences PLC Tiziana Announces Plans to List Accustem in US (2837V)
April 13 2021 - 7:00AM
UK Regulatory
TIDMTILS
RNS Number : 2837V
Tiziana Life Sciences PLC
13 April 2021
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Life Sciences plc Announces Plans to List Accustem
Sciences Limited in the U.S.
NEW YORK and LONDON , April 13, 2021 - Tiziana Life Sciences plc
(NASDAQ: TLSA; LSE : TILS), today announced that its former
subsidiary, Accustem Sciences Limited ("Accustem"), intends to file
a listing application with the Nasdaq Stock Market shortly after
completion of the distribution of shares in Accustem to Tiziana
Life Sciences plc shareholders.
The board of directors of Accustem has resolved that the Nasdaq
listing venue is more appropriate to the nature of Accustem's
business.
About Accustem Sciences
StemPrintER is a multi-gene prognostic assay intended to predict
the risk of recurrence of R+/HER2- breast cancer, and Spare, a
derivative of StemPrintER, combines StemPrintER with two clinical
markers. This gives a more refined risk model.
These assays are intended for the prediction of the risk of
recurrence of breast cancer, based on the detection of 20 stem cell
markers. The assay has been evaluated in an initial retrospective
validation study using a consecutive cohort of approximately 2,400
patients with breast cancer. Subsequently, StemPrintER has been
further validated in an independent retrospective cohort of more
than 800 ER+/HER2- postmenopausal patients from the TransATAC
trial.
A poster presented at the American Society of Clinical Oncology
(ASCO) Virtual Conference in May 2020, demonstrated the superiority
of StemPrintER stem cell based genomic prognostic tool versus the
market leader, Oncotype DX, in predicting recurrence in ER+/HER2-
postmenopausal breast cancer patients.
Endocrine receptor-positive (ER+) breast cancers make up most
breast cancer cases, however display significant variability in
clinical behaviour, this makes prognosis and therapy response
challenging. Although the overall prognosis of patients is good, a
significant proportion of these women will experience distant
recurrence in the first 10 years post-surgery.
For patients who also have a negative HER2 status (HER2-) and
risk of recurrence, the standard of care is endocrine therapy, with
the addition of chemotherapy in patients. However, these parameters
are often insufficient to predict risk of recurrence in ER+/HER2-
breast cancer patients, and consequently, these patients are either
over- or under-treated.
Accustem anticipates this prognostic test to be used in
conjunction with clinical evaluation to identify those patients at
increased risk for early and/or late metastasis.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc (TLSA)
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
U.S. Investor Relations Contact:
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCZZGMDRFNGMZG
(END) Dow Jones Newswires
April 13, 2021 07:00 ET (11:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Oct 2023 to Oct 2024